Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

ICU TopicsInfection / pharmacology

ICU · Infection / pharmacology

Antivirals — Aciclovir, Oseltamivir & the Anti-COVID Agents

Also known as Antiviral · Aciclovir · Acyclovir · Valaciclovir · Ganciclovir · Valganciclovir · Foscarnet · Cidofovir · Oseltamivir · Tamiflu · Zanamivir · Peramivir · Baloxavir · Neuraminidase inhibitor · Remdesivir · Paxlovid · Nirmatrelvir · Molnupiravir · Ribavirin · Antiretroviral · ART

The antivirals in the ICU target the specific viral enzymes. The five ICU-relevant groups: the anti-herpes (the aciclovir — the HSV and the VZV; the DNA polymerase via the thymidine kinase; the NEPHROtoxicity crystal — the hydrate; the HSV encephalitis 10 mg per kg TDS for the 14 to 21 days; the ganciclovir the CMV with the bone-marrow; the foscarnet or the cidofovir the resistant with the nephrotoxic), the anti-CMV (the ganciclovir / the valganciclovir first-line for the transplant and the immunocompromised; the foscarnet and the cidofovir for the resistant or the leucopenic), the anti-influenza (the oseltamivir — the neuraminidase inhibitor; the influenza A and B; the within 48 h of the onset, the severe regardless; the reduces the duration and the complications; the prophylaxis; the zanamivir inhaled, the peramivir IV, the baloxavir the cap-dependent endonuclease), the anti-SARS-CoV-2 (the remdesivir — the RNA polymerase, the severe COVID; the Paxlovid — the nirmatrelvir or the ritonavir protease inhibitor, the early high-risk; the molnupiravir), and the anti-HIV / the ART (the combination antiretroviral therapy — the two NRTIs plus an integrase inhibitor; the ICU the drug-interaction burden, the lactic acidosis, the IRIS, the abacavir hypersensitivity). The renal dosing the critical (the aciclovir, the ganciclovir, the oseltamivir all renally cleared).

medium43 referencesUpdated 26 July 202644 min readSource-verified · Sept 2026

Checked against its sources on 2 Sept 2026

Practise this topic

  • 8 MCQs

Your progress

Saved on this device.

Practise this topic8 MCQs with explanations

Target exams

CICMFFICMEDIC
On this page
Study tools

Your progress

Saved on this device.

Practise this topic8 MCQs with explanations

Target exams

CICMFFICMEDIC
The one-paragraph exam answer

The ICU antivirals sort into five mechanistic families, each aimed at one viral enzyme. Anti-herpes — aciclovir is switched on by the viral thymidine kinase, becomes a triphosphate, and terminates the viral DNA chain; it covers HSV and VZV (not CMV), and its dose-limiting harm is crystal nephropathy. HSV encephalitis is aciclovir 10 mg/kg 8-hourly for 10 days in the pivotal trials, started on suspicion before PCR returns — untreated mortality reaches ~70%, with-aciclovir 19–28%.[15][20] Ganciclovir/valganciclovir hit CMV via the UL97 kinase and cost you the bone marrow; foscarnet and cidofovir are the kinase-independent escape drugs for resistant virus, both nephrotoxic. Anti-influenza — oseltamivir blocks the neuraminidase; treat any severe or ICU influenza regardless of onset time.[6] Anti-COVID — remdesivir for the hypoxic inpatient (recovery, not mortality), Paxlovid for the early high-risk outpatient (89% reduction, but a CYP3A4 minefield).[11] Anti-HIV — combination ART, plus the ICU hazards of tenofovir, abacavir, the d-drugs, and IRIS.[1]

Meet the patient

A 64-year-old man reaches the ED in mid-winter, febrile and unrousable, a day after a flu-like prodrome, and he has a witnessed focal seizure. His GCS is 8, his temperature is 39.1 °C, and he is intubated for airway protection. The differential is wide — but two viral diagnoses are time-critical and will not wait for a PCR: HSV encephalitis and influenza pneumonia.[1]

So without delay you hang empiric aciclovir 10 mg/kg 8-hourly (the regimen randomised in the Swedish encephalitis trial, started on clinical suspicion alone) and give oseltamivir 75 mg via the NG tube twice daily (the standard adult dose used across the oseltamivir trials), alongside broad antibacterials and the septic workup.[15][24] Muthuri's individual-patient meta-analysis advocates early neuraminidase inhibitor treatment in hospitalised adults with suspected or proven influenza — which means not waiting for the PCR — and mortality benefit is greatest within 48 h of symptom onset but extends to later treatment.[6] Hold that first hour in your head — it is the spine of everything that follows.

ICU Fellowship (CICM) Pro

Continue reading

You have read the opening of this topic. The complete unit — every section and its primary-source references — is part of the ICU Fellowship (CICM) fellowship library.

Sign in to continueSee pricing
References43ShowHide
  1. [1]Whitley RJ, Alford CA, Hirsch MS, Schooley RT, Luby JP, Aoki FY, Hanley D, Nahmias AJ, Soong SJ Vidarabine versus acyclovir therapy in herpes simplex encephalitis N Engl J Med, 1986.PMID 3001520
  2. [2]Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant Ann Intern Med, 1993.PMID 8380242
  3. [3]Martin DF, Sierra-Madero J, Walmsley S, et al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis N Engl J Med, 2002.PMID 11948271
  4. [4]Lalezari JP, Holland GN, Kramer F, et al. Randomized, controlled study of the safety and efficacy of intravenous cidofovir for the treatment of relapsing cytomegalovirus retinitis in patients with AIDS J Acquir Immune Defic Syndr Hum Retrovirol, 1998.PMID 9525435
  5. [5]Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group JAMA, 2000.PMID 10697061
  6. [6]Muthuri SG, Venkatesan S, Myles PR, et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data Lancet Respir Med, 2014.PMID 24815805
  7. [7]Dobson J, Whitley RJ, Pocock S, Monto AS Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials Lancet, 2015.PMID 25640810
  8. [8]Hayden FG, Sugaya N, Hirotsu N, et al. Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents N Engl J Med, 2018.PMID 30184455
  9. [9]Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 - Final Report N Engl J Med, 2020.PMID 32445440
  10. [10]WHO Solidarity Trial Consortium Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses Lancet, 2022.PMID 35512728
  11. [11]Hammond J, Leister-Tebbe H, Gardner A, et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 N Engl J Med, 2022.PMID 35172054
  12. [12]Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients N Engl J Med, 2022.PMID 34914868
  13. [13]Jabs DA, Ahuja A, Van Natta M, et al. Comparison of treatment regimens for cytomegalovirus retinitis in patients with AIDS in the era of highly active antiretroviral therapy Ophthalmology, 2013.PMID 23419804
  14. [14]Nguyen-Van-Tam JS, Venkatesan S, Muthuri SG, Myles PR Neuraminidase inhibitors: who, when, where? Clin Microbiol Infect, 2015.PMID 25703253
  15. [15]Sköldenberg B, Forsgren M Acyclovir versus vidarabine in herpes simplex encephalitis Scand J Infect Dis Suppl, 1985.PMID 3912977
  16. [16]Lakeman FD, Whitley RJ Diagnosis of herpes simplex encephalitis: application of the polymerase chain reaction to cerebrospinal fluid from brain-biopsied patients and correlation with disease J Infect Dis, 1995.PMID 7706811
  17. [17]Soul-Lawton J, Seaber E, On N, Wootton R, Rolan P, Posner J Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans Antimicrob Agents Chemother, 1995.PMID 8593015
  18. [18]Höglund M, Ljungman P, Weller S Comparable aciclovir exposures produced by oral valaciclovir and intravenous aciclovir in immunocompromised cancer patients J Antimicrob Chemother, 2001.PMID 11389118
  19. [19]Sawyer MH, Webb DE, Balow JE, Straus SE Acyclovir-induced renal failure. Clinical course and histology Am J Med, 1988.PMID 3376977
  20. [20]AK AK, Bhutta BS, Mendez MD Herpes Simplex Encephalitis StatPearls, 2026.PMID 32491575
  21. [21]Hardy WD Foscarnet treatment of acyclovir-resistant herpes simplex virus infection in patients with acquired immunodeficiency syndrome: preliminary results of a controlled, randomized, regimen-comparative trial Am J Med, 1992.PMID 1531285
  22. [22]Sommadossi JP, Bevan R, Ling T, Lee F, Mastre B, Chaplin MD, Nerenberg C, Koretz S, Buhles WC Jr Clinical pharmacokinetics of ganciclovir in patients with normal and impaired renal function Rev Infect Dis, 1988.PMID 2847287
  23. [23]Kiser TH, Fish DN, Zamora MR Evaluation of valganciclovir pharmacokinetics in lung transplant recipients J Heart Lung Transplant, 2012.PMID 22305377
  24. [24]Kohno S, Kida H, Mizuguchi M, Shimada J Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection Antimicrob Agents Chemother, 2011.PMID 21825298
  25. [25]Hayden FG, Osterhaus AD, Treanor JJ, Fleming DM, Aoki FY, Nicholson KG, Bohnen AM, Hirst HM, Keene O, Wightman K Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections N Engl J Med, 1997.PMID 9302301
  26. [26]Williamson JC, Pegram PS Neuraminidase inhibitors in patients with underlying airways disease Am J Respir Med, 2002.PMID 14720062
  27. [27]Goldman JD, Lye DCB, Hui DS, Marks KM, Bruno R, Montejano R, Spinner CD, Galli M, Ahn MY, Nahass RG Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 N Engl J Med, 2020.PMID 32459919
  28. [28]Török ME, Yen NT, Chau TT, Mai NT, Phu NH, Mai PP, Dung NT, Chau NV, Bang ND, Tien NA, Minh NH, Hien NQ, Thai PV, Dong DT, Anh DT, Thoa NT, Hai NN, Lan NN, Lan NT, Quy HT, Dung NH, Hien TT, Chinh NT, Simmons CP, de Jong M, Wolbers M, Farrar JJ Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)-associated tuberculous meningitis Clin Infect Dis, 2011.PMID 21596680
  29. [29]Abassi M, Boulware DR, Rhein J Cryptococcal Meningitis: Diagnosis and Management Update Curr Trop Med Rep, 2015.PMID 26279970
  30. [30]Meintjes G, Stek C, Blumenthal L, Thienemann F, Schutz C, Buyze J, Ravinetto R, van Loen H, Nair A, Jackson A, Colebunders R, Maartens G, Wilkinson RJ, Lynen L; PredART Trial Team Prednisone for the Prevention of Paradoxical Tuberculosis-Associated IRIS N Engl J Med, 2018.PMID 30428290
  31. [31]Meintjes G, Brust JCM, Nuttall J, Maartens G Management of active tuberculosis in adults with HIV Lancet HIV, 2019.PMID 31272663
  32. [32]LiverTox — National Institute of Diabetes and Digestive and Kidney Diseases Nucleoside Analogues LiverTox [Internet], 2012.PMID 31644243
  33. [33]Morales-Suárez-Varela M, Peraita-Costa I, Llopis-Morales A, Llopis-González A Influenza Vaccination During Pregnancy: A Narrative Review on Maternal and Neonatal Outcomes Associated with Seasonal Influenza Infection Vaccines, 2026.PMID 42506630
  34. [34]Avery RK, Arav-Boger R, Marr KA, Kraus E, Shoham S, Lees L, Trollinger B, Shah P, Ambinder R, Neofytos D, Ostrander D, Forman M, Valsamakis A Outcomes in Transplant Recipients Treated With Foscarnet for Ganciclovir-Resistant or Refractory Cytomegalovirus Infection Transplantation, 2016.PMID 27495775
  35. [35]Fernández S, Castro P, Azoulay E What intensivists need to know about cytomegalovirus infection in immunocompromised ICU patients Intensive Care Med, 2025.PMID 39774866
  36. [36]Onuigbo MA, Nye D, Iloanya PC Drug-induced encephalopathy secondary to non renal dosing of common medications in Two dialysis patients Adv Perit Dial, 2009.PMID 19886325
  37. [37]Uyeki TM, Bernstein HH, Bradley JS, Englund JA, File TM, Fry AM, Gravenstein S, Hayden FG, Harper SA, Hirshon JM, Ison MG, Johnston BL, Knight SL, McGeer A, Riley LE, Wolfe CR, Alexander PE, Pavia AT Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenza Clin Infect Dis, 2019.PMID 30566567
  38. [38]Muthuka JK Jr, Nyamai EM, Oluoch K, Maibvise C, Nabaweesi R Paradoxical and Unmasking HIV Immune Reconstitution Inflammation Syndrome in Antiretroviral-Naïve Pregnant Women: A Prospective Cohort Study Cureus, 2024.PMID 38406047
  39. [39]Yip AJW, Low ZY, Chow VTK, Lal SK Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral Activity Viruses, 2022.PMID 35746815
  40. [40]Ruttmann E, Geltner C, Bucher B, Ulmer H, Höfer D, Hangler HB, Semsroth S, Margreiter R, Laufer G, Müller LC Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation Transplantation, 2006.PMID 16732179
  41. [41]Campbell L, Barbini B, Cromarty B, Hamzah L, Williams D, Winston A, Post FA; FANTA trial team Safety of tenofovir alafenamide in people with HIV who experienced proximal renal tubulopathy on tenofovir disoproxil AIDS, 2024.PMID 38932750
  42. [42]Chamberlain CE, Penzak SR, Alfaro RM, Wesley R, Daniels CE, Hale D, Kirk AD, Mannon RB Pharmacokinetics of low and maintenance dose valganciclovir in kidney transplant recipients Am J Transplant, 2008.PMID 18444933
  43. [43]Whitley RJ Herpes simplex encephalitis: adolescents and adults Antiviral Res, 2006.PMID 16675036

Test yourself

Practise what you just read

  • 8 MCQs
ICU Fellowship (CICM) Pro

$29/ monthor $279 / year

The complete ICU Fellowship (CICM) library, every exam format, one subscription.

  • Complete library for one chosen specialty
  • Timed MCQ mock exams and spaced review
  • Clinical cases & cross-table vivas
See pricingSign in
PreviousAntifungals — Azoles, Echinocandins & Amphotericin BInfection / pharmacologyNextBeta-Lactam Antibiotics — Penicillins, Cephalosporins, Carbapenems, MonobactamsInfection / pharmacology